QQQ   354.89 (+0.19%)
AAPL   170.35 (-0.94%)
MSFT   312.52 (+0.12%)
META   295.41 (-1.19%)
GOOGL   130.20 (+1.27%)
AMZN   125.93 (-0.04%)
TSLA   239.58 (-1.86%)
NVDA   423.95 (+1.15%)
NIO   8.47 (+0.71%)
BABA   86.04 (+0.15%)
AMD   98.19 (+2.32%)
T   14.87 (-1.00%)
F   12.36 (-0.56%)
MU   67.77 (-0.25%)
CGC   0.90 (-2.27%)
GE   110.98 (+0.96%)
DIS   79.85 (-0.25%)
AMC   7.53 (-4.80%)
PFE   32.17 (-0.71%)
PYPL   57.29 (-2.78%)
NFLX   379.06 (-0.05%)
QQQ   354.89 (+0.19%)
AAPL   170.35 (-0.94%)
MSFT   312.52 (+0.12%)
META   295.41 (-1.19%)
GOOGL   130.20 (+1.27%)
AMZN   125.93 (-0.04%)
TSLA   239.58 (-1.86%)
NVDA   423.95 (+1.15%)
NIO   8.47 (+0.71%)
BABA   86.04 (+0.15%)
AMD   98.19 (+2.32%)
T   14.87 (-1.00%)
F   12.36 (-0.56%)
MU   67.77 (-0.25%)
CGC   0.90 (-2.27%)
GE   110.98 (+0.96%)
DIS   79.85 (-0.25%)
AMC   7.53 (-4.80%)
PFE   32.17 (-0.71%)
PYPL   57.29 (-2.78%)
NFLX   379.06 (-0.05%)
QQQ   354.89 (+0.19%)
AAPL   170.35 (-0.94%)
MSFT   312.52 (+0.12%)
META   295.41 (-1.19%)
GOOGL   130.20 (+1.27%)
AMZN   125.93 (-0.04%)
TSLA   239.58 (-1.86%)
NVDA   423.95 (+1.15%)
NIO   8.47 (+0.71%)
BABA   86.04 (+0.15%)
AMD   98.19 (+2.32%)
T   14.87 (-1.00%)
F   12.36 (-0.56%)
MU   67.77 (-0.25%)
CGC   0.90 (-2.27%)
GE   110.98 (+0.96%)
DIS   79.85 (-0.25%)
AMC   7.53 (-4.80%)
PFE   32.17 (-0.71%)
PYPL   57.29 (-2.78%)
NFLX   379.06 (-0.05%)
QQQ   354.89 (+0.19%)
AAPL   170.35 (-0.94%)
MSFT   312.52 (+0.12%)
META   295.41 (-1.19%)
GOOGL   130.20 (+1.27%)
AMZN   125.93 (-0.04%)
TSLA   239.58 (-1.86%)
NVDA   423.95 (+1.15%)
NIO   8.47 (+0.71%)
BABA   86.04 (+0.15%)
AMD   98.19 (+2.32%)
T   14.87 (-1.00%)
F   12.36 (-0.56%)
MU   67.77 (-0.25%)
CGC   0.90 (-2.27%)
GE   110.98 (+0.96%)
DIS   79.85 (-0.25%)
AMC   7.53 (-4.80%)
PFE   32.17 (-0.71%)
PYPL   57.29 (-2.78%)
NFLX   379.06 (-0.05%)
NASDAQ:RVNC

Revance Therapeutics (RVNC) Stock Forecast, Price & News

$12.15
-0.27 (-2.17%)
(As of 02:57 PM ET)
Compare
Today's Range
$12.07
▼
$12.59
50-Day Range
$12.42
▼
$23.63
52-Week Range
$11.10
▼
$37.98
Volume
855,298 shs
Average Volume
1.57 million shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.90
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Revance Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
179.0% Upside
$33.90 Price Target
Short Interest
Bearish
16.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
-0.12mentions of Revance Therapeutics in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$1.72 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.26) to ($1.52) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

237th out of 963 stocks

Pharmaceutical Preparations Industry

96th out of 451 stocks

See Top Rated MarketRank™ Stocks Here

RVNC stock logo

About Revance Therapeutics (NASDAQ:RVNC) Stock

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

RVNC Price History

RVNC Stock News Headlines

September 24, 2023 | americanbankingnews.com
Revance Therapeutics (NASDAQ:RVNC) Trading Up 4.7%
September 23, 2023 | americanbankingnews.com
Revance Therapeutics, Inc. Expected to Post Q3 2023 Earnings of ($1.43) Per Share (NASDAQ:RVNC)
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
September 22, 2023 | 247wallst.com
Goldman Sachs Maintains Revance Therapeutics Buy Recommendation
September 22, 2023 | americanbankingnews.com
Piper Sandler Lowers Revance Therapeutics (NASDAQ:RVNC) Price Target to $44.00
September 22, 2023 | americanbankingnews.com
Revance Therapeutics (NASDAQ:RVNC) Rating Reiterated by HC Wainwright
September 22, 2023 | americanbankingnews.com
Revance Therapeutics (NASDAQ:RVNC) PT Lowered to $35.00
September 22, 2023 | americanbankingnews.com
Revance Therapeutics (NASDAQ:RVNC) Price Target Cut to $33.00
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
September 21, 2023 | americanbankingnews.com
Revance Therapeutics (NASDAQ:RVNC) Sets New 52-Week Low at $11.10
September 20, 2023 | benzinga.com
Discontinuation Of Opul Business Weighs On Botox Rival Revance Therapeutics: Analyst Sees Non-Cash Impairment Charge In Millions
September 19, 2023 | seekingalpha.com
Revance down 16% as investor day update fails to impress
September 19, 2023 | markets.businessinsider.com
What's Going On With Botox Rival Revance Therapeutics' Stock Today?
September 19, 2023 | finance.yahoo.com
Revance Provides Corporate Update at Investor Day
September 18, 2023 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revance Therapeutics (RVNC) and PTC Therapeutics (PTCT)
September 15, 2023 | msn.com
Revance Therapeutics: Impressive Sales Growth/Concerning Cash Burn
September 15, 2023 | seekingalpha.com
Revance's FDA Nod: Beauty, Brains, And Balance Sheets
September 6, 2023 | finance.yahoo.com
Revance Therapeutics (RVNC): A Smart Investment or a Value Trap? An In-Depth Exploration
August 22, 2023 | finance.yahoo.com
Revance to Host Investor Day on September 19, 2023
August 22, 2023 | finance.yahoo.com
‘Load Up,’ Says Goldman Sachs About These 2 ‘Strong Buy’ Stocks
August 21, 2023 | finance.yahoo.com
Revance Therapeutics (RVNC) Shares Declined on Profit-Taking
August 16, 2023 | msn.com
Exane BNP Paribas Upgrades Revance Therapeutics (RVNC)
August 14, 2023 | markets.businessinsider.com
Goldman Sachs Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
August 10, 2023 | msn.com
Morgan Stanley Maintains Revance Therapeutics (RVNC) Equal-Weight Recommendation
August 9, 2023 | benzinga.com
Looking At Revance Therapeutics's Recent Unusual Options Activity
August 9, 2023 | benzinga.com
Where Revance Therapeutics Stands With Analysts
August 9, 2023 | markets.businessinsider.com
Mizuho Securities Remains a Buy on Revance Therapeutics (RVNC)
See More Headlines
Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RVNC Company Calendar

Last Earnings
8/08/2023
Today
9/27/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVNC
CUSIP
N/A
CIK
1479290
Web
www.revance.com
Phone
(615) 724-7755
Fax
510-742-3401
Employees
534
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$33.90
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+179.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-356,420,000.00
Net Margins
-191.93%
Pretax Margin
-191.55%
Return on Equity
-903.28%
Return on Assets
-58.68%

Debt

Debt-to-Equity Ratio
14.20
Current Ratio
5.12
Quick Ratio
4.65

Sales & Book Value

Annual Sales
$132.57 million
Price / Sales
8.06
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.15 per share
Price / Book
81.00

Miscellaneous

Outstanding Shares
87,960,000
Free Float
84,789,000
Market Cap
$1.07 billion
Optionable
Optionable
Beta
0.80
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Mark J. FoleyMr. Mark J. Foley (Age 58)
    CEO & Director
    Comp: $1.33M
  • Mr. Dustin S. Sjuts (Age 43)
    Pres
    Comp: $911.67k
  • Mr. Tobin C. SchilkeMr. Tobin C. Schilke (Age 48)
    CFO & Principal Accounting Officer
    Comp: $753.68k
  • Mr. Dwight MoxieMr. Dwight Moxie (Age 47)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $743.77k
  • Jessica Serra
    Head of Investor Relations & ESG
  • Ms. Jeanie D. Herbert
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Taryn Conway
    VP of Marketing
  • Ms. Amie Krause
    Chief People Officer
  • Dr. Conor Gallagher
    Head of Medical Affairs & Aesthetics
  • Dr. David A. Hollander M.B.A. (Age 49)
    M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RVNC Stock - Frequently Asked Questions

Should I buy or sell Revance Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RVNC shares.
View RVNC analyst ratings or view top-rated stocks.

What is Revance Therapeutics' stock price forecast for 2023?

7 analysts have issued 1 year target prices for Revance Therapeutics' stock. Their RVNC share price forecasts range from $20.00 to $44.00. On average, they expect the company's stock price to reach $33.90 in the next twelve months. This suggests a possible upside of 179.0% from the stock's current price.
View analysts price targets for RVNC or view top-rated stocks among Wall Street analysts.

How have RVNC shares performed in 2023?

Revance Therapeutics' stock was trading at $18.46 at the beginning of 2023. Since then, RVNC shares have decreased by 34.2% and is now trading at $12.15.
View the best growth stocks for 2023 here.

When is Revance Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our RVNC earnings forecast.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.08. The biopharmaceutical company earned $58.13 million during the quarter, compared to analyst estimates of $58.71 million. Revance Therapeutics had a negative trailing twelve-month return on equity of 903.28% and a negative net margin of 191.93%. Revance Therapeutics's revenue was up 104.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.88) EPS.

What ETFs hold Revance Therapeutics' stock?

ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital World Investors (10.89%), JPMorgan Chase & Co. (5.34%), Thrivent Financial for Lutherans (3.69%), Alliancebernstein L.P. (2.95%), State Street Corp (2.33%) and Jennison Associates LLC (2.19%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Carey Oconnor Kolaja, Dustin S Sjuts, Dwight Moxie, Mark J Foley and Tobin Schilke.
View institutional ownership trends.

How do I buy shares of Revance Therapeutics?

Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $12.15.

How much money does Revance Therapeutics make?

Revance Therapeutics (NASDAQ:RVNC) has a market capitalization of $1.07 billion and generates $132.57 million in revenue each year. The biopharmaceutical company earns $-356,420,000.00 in net income (profit) each year or ($4.53) on an earnings per share basis.

How many employees does Revance Therapeutics have?

The company employs 534 workers across the globe.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The official website for the company is www.revance.com. The biopharmaceutical company can be reached via phone at (615) 724-7755, via email at jherbert@revance.com, or via fax at 510-742-3401.

This page (NASDAQ:RVNC) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -